sub:assertion {
  d:DB05389 v:identifier "DB05389" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB05389" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB05389> ;
    dv:drugbank-id "DB05389" ;
    dv:x-cas <http://bio2rdf.org/cas:> ;
    dv:x-chemspider <http://bio2rdf.org/chemspider:2272021> ;
    dv:x-pubchemcompound <http://bio2rdf.org/pubchem.compound:3000391> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:WF10> ;
    dct:description "WF10 is a chlorite-based, immunomodulating drug is developed by Nuvo Research Inc. Certain preclinical evidence and clinical pilot data suggest that WF10 may be effective in treating certain cancers. The Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the body digests foreign, potentially harmful substances. The Corporation has commenced a Phase II clinical trial in an effort to demonstrate the efficacy of WF10 in combination with Xeloda (capecitabine) in the treatment of pancreatic cancer. The trial is being conducted in Germany at the University of Heidelberg and the National Centre for Tumor Diseases."@en ;
    dct:identifier "drugbank:DB05389" ;
    dct:title "WF10"@en ;
    a dv:Drug ;
    rdfs:label "WF10 [drugbank:DB05389]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05389> .
}